<DOC>
	<DOCNO>NCT01144975</DOCNO>
	<brief_summary>The study hypothesis XOMA 052 likely improve glycemic control subject Type 2 Diabetes Mellitus . The purpose study determine whether XOMA 052 improves glycemic control subject Metformin monotherapy whose diabetes still adequately control .</brief_summary>
	<brief_title>Study Safety Biologic Activity XOMA 052 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosed T2D ( disease duration &gt; = 6 month ) HbA1c measurement &gt; = 7.0 % &lt; = 10.0 % On stable regimen metformin monotherapy Age &gt; = 18 &lt; = 75 Stable diet exercise regimen BMI &lt; = 40 kg/m2 Significant sign symptom uncontrolled hyperglycemia ( i.e. , polyuria , polydipsia , polyphagia ) Uncontrolled hypertension ( systolic &gt; 170 mmHg and/or diastolic &gt; 110 mmHg ) Known positive Hep B surface antigen ( HBsAg ) , Hep C virus ( HCV ) , HIV History allergic anaphylactic reaction humanize murine monoclonal antibody Advanced stage heart failure ( New York Heart Association [ NYHA ] class 3 4 ) Pulmonary disease require medication inhale corticosteroid History tuberculosis positive PPD test . Active leg , foot , decubitus ulcer Any significant inflammatory , rheumatologic , systemic autoimmune disease History symptoms demyelinate disease History severe nonproliferative proliferative retinopathy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Mellitus</keyword>
</DOC>